Abstract:
:Diquafosol ophthalmic solution 3 % (Diquas(®)) is a P2Y2 receptor agonist that promotes tear fluid and mucin secretion and is currently approved in Japan and South Korea for the treatment of dry eye. In randomized, double-blind, multicentre trials in patients with dry eye, significantly greater improvements in fluorescein and rose bengal staining scores were seen with diquafosol ophthalmic solution 3 % than with placebo, and diquafosol ophthalmic solution 3 % was noninferior to sodium hyaluronate ophthalmic solution 0.1 % in terms of the improvement in the fluorescein staining score and more effective than sodium hyaluronate ophthalmic solution 0.1 % in terms of the improvement in the rose bengal staining score. The efficacy of diquafosol ophthalmic solution 3 % in the treatment of dry eye was maintained in the longer term, with improvements also seen in subjective dry eye symptoms, and was also shown in a real-world setting. Diquafosol ophthalmic solution 3 % also demonstrated efficacy in various specific dry eye disorders, including aqueous-deficient dry eye, short tear film break-up time dry eye, obstructive meibomian gland dysfunction, dry eye following laser in situ keratomileusis surgery and dry eye following cataract surgery, as well as in contact lens wearers and visual display terminal users. Diquafosol ophthalmic solution 3 % was generally well tolerated in patients with dry eye, with eye irritation the most commonly reported adverse event. In conclusion, diquafosol ophthalmic solution 3 % is a useful option for the treatment of dry eye.
journal_name
Drugsjournal_title
Drugsauthors
Keating GMdoi
10.1007/s40265-015-0409-7subject
Has Abstractpub_date
2015-05-01 00:00:00pages
911-22issue
8eissn
0012-6667issn
1179-1950journal_volume
75pub_type
杂志文章,评审相关文献
DRUGS文献大全abstract:UNLABELLED:Candesartan cilexetil is converted to the angiotensin II receptor antagonist candesartan during absorption from the gastrointestinal tract. The selective and competitive binding of candesartan to the angiotensin II type 1 (AT(1)) receptor prevents binding of angiotensin II, a key mediator in the renin-angiot...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200262080-00016
更新日期:2002-01-01 00:00:00
abstract::When used to treat patients with Parkinson's disease pergolide acts at dopamine receptors in the corpus striatum to improve locomotor activity, reducing the tremor, gait disturbances, bradykinesia or akinesia and rigidity experienced by such patients. Treatment with pergolide often allows substantial reductions in con...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199039030-00009
更新日期:1990-03-01 00:00:00
abstract::The newest (third generation) fluoroquinolones are potentially useful agents in the management of community-acquired respiratory tract infections. This is mainly due to their increased activity against Streptococcuspneumoniae, a pathogen poorly susceptible to the second-generation compounds, and playing a major role i...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199957060-00002
更新日期:1999-06-01 00:00:00
abstract:INTRODUCTION:Authorization of orphan medicinal products (OMPs) is often based on studies with several methodological shortcomings. Hence, data are difficult to interpret and efficacy does not always correspond to real-world effectiveness. We investigated to what extent an efficacy-effectiveness gap exists for OMPs for ...
journal_title:Drugs
pub_type: 杂志文章
doi:10.1007/s40265-017-0788-z
更新日期:2017-09-01 00:00:00
abstract::Sitagliptin (Januvia(®), Xelevia™, Glactiv(®), Tesavel(®)) is an orally administered, potent and highly selective inhibitor of dipeptidyl peptidase-4 (DPP-4) and was the first agent of its class to be approved for use in the management of adults with type 2 diabetes. Numerous randomized placebo- or active comparator-c...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-013-0169-1
更新日期:2014-02-01 00:00:00
abstract::The aim of the Helsinki Heart Study, a 5-year primary prevention placebo-controlled study involving 4081 dyslipidaemic men (aged 40 to 55 years), was to investigate if increasing high density lipoprotein (HDL)-cholesterol plasma levels and decreasing low density lipoprotein (LDL)-cholesterol levels would reduce the in...
journal_title:Drugs
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.2165/00003495-199000401-00004
更新日期:1990-01-01 00:00:00
abstract::Metabolites of arachidonic acid have a broad range of physiological functions in the gastrointestinal tract, and seem to be involved in certain disturbances of gastrointestinal integrity and function. Prostaglandins inhibit gastric acid secretion, apparently via an adenylate cyclase-linked receptor, and also stimulate...
journal_title:Drugs
pub_type: 杂志文章
doi:10.2165/00003495-198700331-00007
更新日期:1987-01-01 00:00:00
abstract::Mantle cell lymphoma is a rare yet well defined subtype of B-cell non-Hodgkin's lymphoma. The correct histological diagnosis of this lymphoma subtype is of the utmost importance; however, it is also a very difficult diagnosis. Clinical management is often complex, and despite the successful introduction of monoclonal ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200767120-00004
更新日期:2007-01-01 00:00:00
abstract::Sitagliptin (Januvia, Glactiv(R), Tesavel(R)) is a dipeptidyl peptidase-4 inhibitor indicated for the treatment of type 2 diabetes mellitus. Oral sitagliptin as monotherapy or combination therapy was generally well tolerated and improved glycaemic control in well designed clinical trials in patients with type 2 diabet...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/11203790-000000000-00000
更新日期:2010-03-05 00:00:00
abstract::During recent decades, undeniable progress has been made with regard to the management of arterial hypertension. Larger numbers of patients are aware they have hypertension, receive treatment and benefit from this therapy. Furthermore, significant reductions have been observed in morbidity and mortality resulting from...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199856002-00004
更新日期:1998-01-01 00:00:00
abstract::Hypertension affects 65 million people in the US, and is a major cause of morbidity and mortality, but less than one-third of patients with hypertension are treated to goal blood pressure. Multiple factors have been cited, and include suboptimal adherence to treatment and lifestyle modifications, limited access to hea...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200666090-00006
更新日期:2006-01-01 00:00:00
abstract::Hypertension in pregnancy has implications for both maternal and fetal welfare. Extrapolation from concepts of mechanisms operating in hypertension in general to pregnancy-related hypertension is not justified. In the latter, the major features are a hyper-adrenergic state, plasma volume reduction and an increased sys...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-198428020-00005
更新日期:1984-08-01 00:00:00
abstract:UNLABELLED:Enoxaparin (enoxaparin sodium) is a low molecular weight heparin (LMWH) that is widely used in the prevention of deep venous thrombosis and pulmonary embolism in patients undergoing orthopaedic or general surgery. Its efficacy in these indications has led to study of its use in patients with coronary artery ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199856020-00013
更新日期:1998-08-01 00:00:00
abstract::The new therapeutic options available to clinicians treating dyslipidaemia in the last decade have enabled effective treatment for many patients. The development of the HMG-CoA reductase inhibitors (statins) have been a major advance in that they possess multiple pharmacological effects (pleiotropic effects) resulting...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200060010-00005
更新日期:2000-07-01 00:00:00
abstract::ROS1 gene rearrangements exist in 1-2% of non-small cell lung cancers, typically occurring in younger, never or light smokers with adenocarcinoma. ROS1 gene fusions are potent oncogenic drivers, the presence of which results in the susceptibility of tumours to ROS1-targeted therapy. Crizotinib was the first tyrosine k...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-019-01164-3
更新日期:2019-08-01 00:00:00
abstract::Nizatidine is an H2-receptor antagonist which in animal studies was more active on a weight-for-weight basis than cimetidine in inhibiting basal and stimulated gastric acid secretion. Similarly, studies in humans have confirmed that nizatidine is a potent inhibitor of basal, nocturnal and stimulated gastric acid secre...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-198836050-00002
更新日期:1988-11-01 00:00:00
abstract::Bevacizumab is a recombinant, humanized anti-vascular endothelial growth factor (VEGF) monoclonal antibody that neutralizes the biological activity of VEGF and inhibits tumour angiogenesis. In two pivotal, well designed, phase III, clinical trials (GOG-0218 and ICON7) in women with advanced epithelial ovarian, fallopi...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/11208940-000000000-00000
更新日期:2012-05-07 00:00:00
abstract::This article is intended to stimulate thought and focus on those areas where we feel advances in drug therapy for inflammatory bowel disease may occur. It is not an extensive review of current practice, although this is considered where it is thought to be pertinent to future developments. There are several excellent ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199753020-00001
更新日期:1997-02-01 00:00:00
abstract::Induction of labour, defined as stimulation of uterine contractions before the spontaneous onset of labour, is indicated when the condition of the mother or fetus precludes awaiting the onset of spontaneous labour. In current medical practice, induction of labour comprises 2 phases: cervical priming and induction of c...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199754010-00005
更新日期:1997-07-01 00:00:00
abstract::Desloratadine is the orally active major metabolite of the nonsedating H1-antihistamine loratadine. The drug had no adverse cardiovascular effects in various animal models or when administered at 9 times the recommended adult dosage for 10 days in volunteers. Therapeutic dosages had no effects on wakefulness or psycho...
journal_title:Drugs
pub_type: 杂志文章
doi:10.2165/00003495-200161060-00007
更新日期:2001-01-01 00:00:00
abstract::Developments in drug delivery technology have expanded the formulations of 5-aminosalicylic acid (5-ASA) available to clinicians over the last 50 years. Delivery of adequate doses of 5-ASA to the colon can be achieved by pH-dependent, delayed-release or pro-drug formulations. Despite some variations in the pharmacokin...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200868080-00006
更新日期:2008-01-01 00:00:00
abstract::Serious hepatotoxicity is uncommon with the proper therapeutic use of non-narcotic analgesics but experience with new non-steroidal anti-inflammatory drugs (NSAIDs) is limited. Drugs such as ibufenac, fenclofenac and benoxaprofen were withdrawn from the market because of hepatotoxicity, and liver damage has been repor...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-198600324-00010
更新日期:1986-01-01 00:00:00
abstract::Acamprosate (Campral(®), Aotal(®), Regtect(®)) is one of a limited number of pharmacological treatment options approved as an adjunct to psychosocial interventions to facilitate the maintenance of abstinence in alcohol-dependent patients. It has been used in Europe, the USA and other countries for many years and was r...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-015-0423-9
更新日期:2015-07-01 00:00:00
abstract::Antibacterial activities of cefotaxime and its major metabolite, desacetylcefotaxime, against 178 strains (of 10 species) were assessed in terms of minimum inhibitory concentrations (MIC50 and MIC80), and were compared with those of cefoperazone and ceftazidime. The activity of desacetylcefotaxime was several times le...
journal_title:Drugs
pub_type: 杂志文章
doi:10.2165/00003495-198800352-00013
更新日期:1988-01-01 00:00:00
abstract::In human lung tissue in vitro, nedocromil sodium inhibited the release of histamine and leukotrienes induced by anti-IgE, as well as the contraction of isolated bronchi which followed this challenge. In the hamster cheek pouch in vivo, nedocromil sodium inhibited the inflammatory response induced by challenge with eit...
journal_title:Drugs
pub_type: 杂志文章
doi:10.2165/00003495-198900371-00013
更新日期:1989-01-01 00:00:00
abstract::Letermovir (Prevymis™) is an orally or intravenously administered cytomegalovirus (CMV) DNA terminase complex inhibitor being developed by Merck & Co., Inc., under a global license from AiCuris Anti-infective Cures GmbH. Letermovir has been approved in Canada and the USA for the prophylaxis of CMV infection and diseas...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-017-0860-8
更新日期:2018-01-01 00:00:00
abstract::The advent of thrombolytic therapy was a major advance in the treatment of ST-segment elevation myocardial infarction (STEMI). The administration of fibrinolytic reperfusion therapy can reduce mortality rates by as much as 30%, with the greatest benefit observed if therapy is administered soon after symptom onset. Out...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/11317670-000000000-00000
更新日期:2009-10-01 00:00:00
abstract::Trigeminal neuralgia is a representative neuropathic facial pain condition, characterised by unilateral paroxysmal pain in the distribution territory of one or more divisions of the trigeminal nerve, triggered by innocuous stimuli. A subgroup of patients with trigeminal neuralgia [TN (previously defined as atypical TN...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-018-0964-9
更新日期:2018-09-01 00:00:00
abstract::Cenegermin (Oxervate™), an ophthalmic solution containing 20 µg/mL of recombinant human nerve growth factor (rhNGF), is the first drug to be approved for the treatment of neurotrophic keratitis (NK; also referred to as neurotrophic keratopathy). In the registration trials, the majority of adults with moderate or sever...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-020-01289-w
更新日期:2020-04-01 00:00:00
abstract::The article Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection, written by Emma D. Deeks, was originally published Online First without open access. After publication in volume 78, issue 17, pages 1817-1828 Gilead Sciences requested that the article be Open Choice to make the article an open ...
journal_title:Drugs
pub_type: 杂志文章,已发布勘误
doi:10.1007/s40265-019-01101-4
更新日期:2019-04-01 00:00:00